TriSalus Life Sciences Inc.

TriSalus Life Sciences, Inc. researches, develops, and commercializes a drug delivery technology platform and immuno-oncology therapeutics for difficult-to-treat liver and pancreatic cancers in the United States. Its Pressure-Enabled Drug Delivery (PEDD) infusion systems include the TriNav infusion system, used in transarterial radioembolization and chemoembolization for liver cancer and metastases, and the Pancreatic Retrograde Venous Infusion device, in Phase 1 trials for locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 trials for uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. Founded in 2009, it is headquartered in Westminster, Colorado, and serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff.